Eirgen Pharma to Attend euroPLX Warsaw: Advancing In-Licensing and Out-Licensing Opportunities

Meet Sarah Wade

We are pleased to announce that Eirgen Pharma will be attending EuroPLX Warsaw, a leading European event dedicated to business development, deal-making, and licensing within the life sciences sector.

EuroPLX is designed to facilitate high-quality, pre-scheduled one-to-one meetings between pharmaceutical and biotech companies. With a strong focus on in-licensing and out-licensing, the event provides a unique environment to explore:

• Acquisition of new products and pipeline assets

• Out-licensing opportunities for developed or commercial-ready products

• Co-development and strategic partnerships

• Market expansion through regional licensing agreements

  
  

For Eirgen Pharma, this creates an ideal setting to engage with companies looking to unlock value across their portfolios.

While Eirgen is widely recognised as a research-driven CDMO specialising in oral solid dose (OSD) development and manufacturing, our role within the ecosystem extends further.

We actively support partners across both in-licensing, and out-licensing.

Let's Connect in Warsaw!

Our Business Development team will be attending EuroPLX Warsaw and is available to discuss:

• In-licensing opportunities

• Out-licensing strategies

• Development and manufacturing support for licensed assets

• Long-term partnership models

• 
  

If you are attending and would like to explore how Eirgen Pharma can support your licensing objectives, we encourage you to schedule a meeting with our team.